2025-04-05 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**0) Summary Statistics:**

* **Ticker:** UNH
* **Company:** UnitedHealth Group Inc. - A diversified healthcare company providing health benefits and services.
* **Cumulative Return (UNH):** 88.28%
* **Cumulative Return (VOO):** 71.02%
* **Return Difference (UNH - VOO):** 17.26%
* **Relative Outperformance (vs. VOO):** 44.7% (based on historical range of -28.4% to 73.8%)


**1) Performance Comparison and Alpha/Beta Analysis:**

UNH has significantly outperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return exceeding VOO by 17.26%.  The relative outperformance of 44.7% suggests a strong performance compared to its historical context against the S&P 500.

The Alpha/Beta analysis shows fluctuating performance relative to the market.  While Alpha is generally positive, indicating outperformance, it's not consistently high and has even been negative in recent periods (2022-2025).  The Beta fluctuates around 0.3-0.5, signifying moderate sensitivity to market movements.  The company's market capitalization has steadily increased over the years.  Note that the CAGR (Compound Annual Growth Rate) and Maximum Drawdown (MDD) figures reflect past performance and are not indicative of future results.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 64.0% | 56.1% | 34.0% | 0.1 | 181.0 |
| 2016-2018  | 55.0% | 63.9% | 38.0% | 0.3 | 207.3 |
| 2017-2019  | 41.0% | 63.9% | 12.0% | 0.3 | 248.8 |
| 2018-2020  | 6.0% | 63.9% | -23.0% | 0.5 | 301.7 |
| 2019-2021  | 74.0% | 17.0% | 0.0% | 0.5 | 438.0 |
| 2020-2022  | 62.0% | 65.5% | 42.0% | 0.5 | 468.4 |
| 2021-2023  | 42.0% | 67.8% | 14.0% | 0.4 | 472.1 |
| 2022-2024  | -35.0% | 68.9% | -50.0% | 0.3 | 460.8 |
| 2023-2025  | -22.0% | 73.5% | -25.0% | 0.1 | 480.3 |


**2) Recent Price Movement:**

* **Closing Price:** $525.05
* **Previous Close:** $540.44
* **Change:** -$2.85 (a decrease of 0.53%)
* **5-Day Moving Average:** $527.11
* **20-Day Moving Average:** $508.36
* **60-Day Moving Average:** $510.85

The price is currently below its 5-day and 60-day moving averages, suggesting a short-term downward trend. However, it's above the 20-day moving average, which could indicate potential support.  The recent price drop reflects a significant negative change.


**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4693 (High Risk)
* **RSI:** 68.31 (Approaching overbought territory)
* **PPO:** 0.5755 (Positive, suggesting upward momentum)
* **20-Day Relative Divergence Change:** +19.7% (Short-term upward trend)
* **Expected Return (Long-term):** 36.2% (vs. S&P 500)


The high MRI indicates a high-risk profile, while the RSI suggests the stock might be overbought.  However, the positive PPO and recent relative divergence indicate upward momentum. The significant negative change in the last market data suggests a potential short-term correction or volatility. The long-term expected return is quite substantial, exceeding the S&P 500 significantly.


**4) Recent Earnings Analysis:**

The earnings data shows some volatility. While revenue generally shows growth, EPS fluctuates significantly, even showing a negative value in one quarter (2024-05-09).  Further investigation is needed to understand the reasons behind the EPS variability.

| Date       | EPS   | Revenue         |
|------------|-------|-----------------|
| 2024-11-04 | 6.56  | $100.82 B       |
| 2024-08-09 | 4.58  | $98.86 B        |
| 2024-05-09 | -1.53 | $99.80 B        |
| 2023-11-06 | 6.31  | $92.36 B        |
| 2024-11-04 | 6.31  | $92.36 B        | *(Duplicate Data)*


**5) Financial Information:**

Revenue remains relatively stable and shows consistent growth. Profit margins are generally high and consistent, exceeding 20%.  ROE (Return on Equity) also shows fluctuations, including a negative value in one quarter, likely correlating with the negative EPS in the same period. This requires further investigation to identify the underlying causes.


Revenue and Profitability:

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |
| 2024-06-30 | $98.86B   | 22.31%        |
| 2024-03-31 | $99.80B   | 23.05%        |
| 2023-12-31 | $94.43B   | 23.30%        |

Capital and Profitability:

| Quarter | Equity     | ROE   |
|---------|------------|-------|
| 2024-12-31 | $92.66B   | 5.98% |
| 2024-09-30 | $94.53B   | 6.41% |
| 2024-06-30 | $89.36B   | 4.72% |
| 2024-03-31 | $86.69B   | -1.63%|
| 2023-12-31 | $88.76B   | 6.15% |



**6) Overall Analysis:**

UNH has demonstrated strong historical outperformance against the S&P 500, with a considerably high projected long-term return.  However, recent price action shows short-term weakness, and some key financial metrics (EPS, ROE) exhibit volatility. The high Market Risk Indicator also signals caution.  While the long-term outlook appears positive given its historically strong performance and projected return, investors should carefully consider the recent price decline, the volatility in earnings and ROE, and the high-risk assessment before making any investment decisions.  Further analysis of the causes behind the recent price drop and the fluctuations in EPS and ROE is crucial.  This review highlights the need for in-depth due diligence and potentially incorporating risk management strategies.
